Vaccination and auto-immunity : reassessing evidence Marc GIRARD, MSc, MD 1 bd de la République 78000-Versailles (France) Vaccination, Infection & Automminunity:

Slides:



Advertisements
Similar presentations
Evaluating Adverse Events after Vaccination in the Medicare Population Robert Ball, MD, MPH, ScM Chief, Vaccine Safety Branch Division of Epidemiology.
Advertisements

Feb 2011 Dr Guada Lopez Marti Pediatric Infectious Diseases Marshall University.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
PROTECTING BABIES THROUGH IMMUNIZATION SAFE AND HEALTHY BABIES.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
THE OCCUPATIONAL HEALTH PROGRAM FOR ANIMAL RELATED ACTIVITIES KATHRYN WIENS – INTERIM OCCUPATIONAL HEALTH PROGRAM ADMINISTRATOR.
IMMUNIZATIONS HEALTHROOM ASSISTANT TRAINING Cheri Dotson, RN, BSN, MA
Medicinal Chemistry 401: Immunizing Agents 2007 Instructor: Valerie Daggett, Date TimeLecturerTopicReadingsSlides 5/48:30 amDaggett.
Vaccine Education Module: Vaccines Updated: April 2013.
ELIZABETH WILLIAMS, MD FELLOW IN VACCINOLOGY AND VACCINE SAFETY VANDERBILT UNIVERSITY AUGUST 30 TH, 2012 Thimerosal and Vaccine Safety.
Why Vaccines Are Important for Children
Vaccine Safety Concerns  Past of vaccines  Now most parents have never seen a case of diphtheria, measles, or other once- common diseases.  They therefore.
Public Health Preventive Medicine primary prevention specific prevention immunization Samar Musmar,MD,FAAFP Consultant, family medicine Clinical assistant.
The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Jeff Neccuzi, Director Division of Immunization Services WV Bureau for Public Health.
MEASLES VACCINATION 2015 Update Susan Reeser RN, BSN (406)
What are the 5 pathogens we’ve discussed in class?
1 The European Paediatric Initiative Agnès Saint Raymond, MD Scientific Advice and Orphan Drugs The European Medicines Evaluation Agency.
A Comprehensive Policy framework for the National Immunization Programme Dr Nihal Abeysinghe, [M.B.,B.S., MSc, M.D.] Chief Epidemiologist, Ministry of.
VAERS Analysis SaneVax Inc. ©2012. Total Adverse Events Gardasil (HPV4)was approved for use in June This chart represents the vaccines most frequently.
Vaccines.  Learning Intention:  Today we are learning and exploring the importance of vaccines on our and the community’s health.  Success Criteria:
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.
Respond Detect Report Investigate Adverse Events Following Immunization Dr S.M.Zahraei Center for Disease Control Ministry of Health and Medical Education.
In healthy adults Naisi Zhao LIVE AEROSOL VACCINES.
From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.
Economic Evaluation of Routine Childhood Immunization with DTaP, Hib, IPV, MMR and HepB Vaccines in the United States, 2001 Fangjun Zhou Health Services.
30th anniversary of starting EPI
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
5th Annual Advocacy Project: ImmuneWise Section on Medical Students, Residents, and Fellowship Trainees
1 Non-Sedating Antihistamines Rx-to-OTC Switch NDAC & PADAC Joint Meeting May 11, 2001 François Nader, MD Senior Vice-President Medical & Regulatory Affairs,
An Evolution to Public Health : The Autobiography of an Infection Disease Pediatrician. Kenneth J. Bart, MD, MPH, MSHPM.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
“Immunizations” What Parents Should Know. The Immune System DEFINITION: Body’s method of protecting itself from foreign substances that invade the body.
“Immunizations” What Parents Should Know Parenting Class.
Influenza Prevention and Treatment for the Season Faculty Stefan Gravenstein, MD, MPH Professor of Medicine The Center for Geriatric Medicine.
Safety of IVIgG Elspeth McIntosh SNBTS Medical Information and Pharmacovigilance Manager.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.
Hepatitis A Issues and IAPCOI perspectives Dr Monjori Mitra Associate Professor Institute of Child Health Kolkata.
Administering Injections and Immunizations
Presentation Outline Introduction Reasons to Immunize Adults: Make the Case Myths vs. Facts Barriers to Adult Immunization The Ask Adult Immunization Resources.
What are the health benefits and risks associated with vaccinating your child and why is it so important ?
MANDATORY CHILDHOOD IMMUNIZATIONS AND ADOLESCENT HUMAN PAPILLOMAVIRUS (HPV): NO SHOTS – NO SCHOOL AUDREY MUNN AMY ROELSE.
Update from the Office of Vaccines Research and Review, CBER/FDA NVAC Meeting Washington, D.C. February 4-5, 2003.
The different types of vaccines used and their composition.
Job Corps Webinar: Immunizations John Kulig MD MPH Lead Medical Specialist September 29 & 30, 2010.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
Principles of Vaccination Epidemiology and Prevention of Vaccine- Preventable Diseases Source: Centers for Disease Control and Prevention.
NEW TECHNOLOGIES IN VACCINES. Vaccination – is the introduction into the body of a weakened, killed or piece of a disease-causing agent to prevent disease.
National Vaccine Injury Compensation Program HRSA The National Vaccine Injury Compensation Program (VICP): What’s New? National Immunization Conference.
TM Influenza Vaccine Safety in Children: Data from VAERS John Iskander MD MPH Gina Mootrey DO MPH Penina Haber MPH Roseanne English-Bullard BS.
Using Surveillance Indicators for Vaccine-Preventable Diseases: National Notifiable Diseases Surveillance System Sandra W. Roush, MT, MPH National.
Inventions Research & Development (R&D) in Pharmaceuticals DISCOVERY Enzymes, receptors, & genetics, DEVELOPMENT Safety, quality and efficacy tests PRODUCTION.
Innovation and the Pharmaceutical Research and Development Industry January 2002 MSD South Africa.
Efficacy and Safety of Medicines
Vaccine Education Module: Vaccines Updated: February 2015
ACIP Feb , 2007 Guillain-Barré Syndrome (GBS) Among Recipients of Meningococcal Conjugate Vaccine (MCV4,Menactra®) Update Oct Jan Robert.
Community Health Indicators
Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events
Innovation & the Pharmaceutical Research & Development Industry
Vaccines.
Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.
Immunizations for Young Children
Racial and ethnic disparities in childhood immunization rates have declined as overall coverage increased. Percentage of children ages 19 to 35 months.
Prioritizing Prevention of HPV-Related Disease
INTENTIONAL HUMAN DOSING STUDIES (IHDS)
Immunization Safety Office (ISO) National Immunization Program (NIP)
Presentation transcript:

Vaccination and auto-immunity : reassessing evidence Marc GIRARD, MSc, MD 1 bd de la République Versailles (France) Vaccination, Infection & Automminunity: Myth & Reality (Lausanne, October 2005)

Auto-immune hazards Individual toxicity (1 vaccine) Additive effect (  2 vaccines) Interactive effect (  2 vaccines) + +

“ADVERSE REACTIONS ENGERIX-B is generally well tolerated (…) In 36 clinical studies, a total of 13,495 doses of ENGERIX-B were administered to 5,071 healthy adults and children (…) All subjects were monitored for 4 days post-administration (…)”. Physician Desk Reference

“(…) Researchers analysed the US Vaccine Adverse Event Reporting System (VAERS) database for serious neurological symptoms (…) MHRA dismisses study findings (…) The MHRA notes that the authors failed to consider the limitations and biases inherent in VAERS data (…)”. MHRA: Study on safety of MMR vaccine by Geier and Geier - conclusions are not justified. Internet-Document, 22 May 2003.

“ (…) The Vaccine Adverse Event Reporting System (VAERS) in the US is a useful surveillance system for ensuring the safety of vaccines, according to researchers from the US FDA and Centres for Disease Control and Prevention (CDC) (…)” Morbidity-and-Mortality-Weekly-Report, vol. 52, page 1-26, 24 January 2003

“(…) Since tolcapone was marketed, there had been 10 reports of serious hepatic adverse reactions (…) The CPMP considered that the overall balance of risks and benefits of tolcapone was no longer favourable (…) Consequently, tolcapone was voluntarily withdrawn (…)” Current Problem in Pharmacovigilance (25 Feb 1999)

VaccineNumber of case reports prior to HBV42102 Measle or MMR2040 Tetanus or DTP1327 Haemophilus influenzae type b 47 Polio or DTP33 Published case reports on various vaccine hazards in REACTIONS database

Data of health insurance system (France)

“Dear Dr Girard On the basis of the advice I have received I have decided not to go ahead with your publication. X… Emeritus Professor of Science and Engineering Ethics”

Conclusions Vaccine R&D: the zero-level of EBM HBV: unusually toxic (esp. for a vaccine) A moral responsibility for each of us